Geoffrey A Donnan Selected Research

Tenecteplase

1/2022	Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial.
1/2022	Thrombectomy versus Medical Management in Mild Strokes due to Large Vessel Occlusion: Exploratory Analysis from the EXTEND-IA Trials and a Pooled International Cohort.
1/2022	Reduced Severity of Tissue Injury Within the Infarct May Partially Mediate the Benefit of Reperfusion in Ischemic Stroke.
1/2022	Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (Mobile Stroke Unit-TASTE-A): protocol for a prospective randomised, open-label, blinded endpoint, phase II superiority trial of tenecteplase versus alteplase for ischaemic stroke patients presenting within 4.5 hours of symptom onset to the mobile stroke unit.
11/2021	Association between pre-treatment perfusion profile and cerebral edema after reperfusion therapies in ischemic stroke.
12/2020	Cost-Effectiveness of Tenecteplase Before Thrombectomy for Ischemic Stroke.
1/2020	Comparing mismatch strategies for patients being considered for ischemic stroke tenecteplase trials.
1/2020	Determining the optimal dose of tenecteplase before endovascular therapy for ischemic stroke (EXTEND-IA TNK Part 2): A multicenter, randomized, controlled study.
1/2020	Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial.
10/2018	Volumetric and Spatial Accuracy of Computed Tomography Perfusion Estimated Ischemic Core Volume in Patients With Acute Ischemic Stroke.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Geoffrey A Donnan Research Topics

Disease

152	Stroke (Strokes) 02/2022 - 01/2002
103	Ischemic Stroke 02/2022 - 01/2002
27	Infarction (Infarctions) 01/2022 - 01/2002
13	Hemorrhage 03/2022 - 01/2010
9	Cerebral Hemorrhage 03/2022 - 06/2006
8	Hypertension (High Blood Pressure) 01/2022 - 02/2002
8	Cerebral Infarction 01/2020 - 01/2002
7	Atrial Fibrillation 10/2019 - 04/2002
6	Hematoma 03/2022 - 11/2013
6	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 09/2002
6	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2017 - 09/2008
5	Brain Edema (Cerebral Edema) 01/2022 - 08/2013
5	Edema (Dropsy) 01/2022 - 08/2013
5	Ischemia 08/2018 - 05/2004
4	Arterial Occlusive Diseases (Arterial Occlusive Disease) 01/2022 - 01/2014
4	Dementia (Dementias) 01/2021 - 10/2004
4	Brain Ischemia (Cerebral Ischemia) 05/2012 - 01/2008
3	Carotid Stenosis (Carotid Artery Stenosis) 10/2019 - 01/2004
3	Body Weight (Weight, Body) 01/2018 - 03/2015
3	Transient Ischemic Attack 01/2017 - 05/2012
3	Cognitive Dysfunction 01/2017 - 10/2008
3	Hypoxia (Hypoxemia) 03/2011 - 07/2006
2	Thrombosis (Thrombus) 05/2019 - 01/2018
2	Inflammation (Inflammations) 01/2016 - 01/2006
2	Embolism (Embolus) 05/2014 - 04/2012
2	Hypothermia 08/2013 - 12/2007
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 03/2011 - 09/2003
1	COVID-19 05/2022
1	Hemorrhagic Stroke 01/2021
1	Frailty 01/2021
1	Chronic Renal Insufficiency 01/2021
1	Wounds and Injuries (Trauma) 12/2020
1	Intracranial Thrombosis (Cerebral Thrombosis) 01/2020
1	Neurologic Manifestations (Neurological Manifestations) 01/2019
1	Hyperglycemia 01/2019
1	Neoplasms (Cancer) 10/2018

Drug/Important Bio-Agent (IBA)

61	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2022 - 01/2005
18	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2021 - 05/2004
15	Tenecteplase FDA Link 01/2022 - 01/2014
14	Biomarkers (Surrogate Marker)IBA 01/2022 - 04/2004
9	Neuroprotective AgentsIBA 08/2018 - 05/2004
8	Pharmaceutical PreparationsIBA 08/2018 - 05/2004
6	Cytidine Triphosphate (CTP)IBA 10/2018 - 01/2008
6	Warfarin (Coumadin)FDA LinkGeneric 05/2014 - 05/2004
5	Antihypertensive Agents (Antihypertensives)IBA 01/2020 - 08/2013
5	Biological ProductsIBA 01/2020 - 03/2009
5	fluoromisonidazoleIBA 03/2011 - 02/2004
4	Tranexamic Acid (AMCA)FDA Link 03/2022 - 06/2014
4	CholesterolIBA 10/2019 - 02/2002
4	Clopidogrel (Plavix)FDA Link 05/2014 - 11/2004
3	Fibrinolytic Agents (Antithrombotic Agents)IBA 01/2022 - 06/2011
3	Indicators and Reagents (Reagents)IBA 01/2020 - 08/2018
3	Glucose (Dextrose)FDA LinkGeneric 01/2019 - 12/2014
3	disufenton sodium (NXY 059)IBA 08/2018 - 08/2006
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2018 - 01/2008
3	Angiotensin Receptor AntagonistsIBA 09/2009 - 09/2008
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 06/2015
2	Complement System Proteins (Complement)IBA 01/2020 - 01/2016
2	LipidsIBA 01/2018 - 01/2012
2	ORALIT (ORS)IBA 07/2017 - 06/2005
2	Glyburide (Glibenclamide)FDA LinkGeneric 08/2014 - 01/2014
2	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 05/2012 - 12/2010
2	Amyloid (Amyloid Fibrils)IBA 05/2012 - 12/2010
2	Desmodus rotundus salivary plasminogen activator alpha 1IBA 01/2010 - 03/2009
2	Dipyridamole (Persantine)FDA LinkGeneric 10/2008 - 09/2008
2	Telmisartan (Micardis)FDA Link 10/2008 - 09/2008
2	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 05/2008 - 01/2008
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2008 - 04/2002
2	Perindopril FDA LinkGeneric 06/2003 - 02/2003
2	Heparin (Liquaemin)FDA LinkGeneric 04/2003 - 01/2003
1	FibrinIBA 05/2022
1	GadoliniumIBA 01/2022
1	Plasminogen Activators (Plasminogen Activator)IBA 01/2022
1	VitronectinIBA 01/2020
1	ClusterinIBA 01/2020
1	Complement C9 (Complement Component 9)IBA 01/2020
1	Edetic Acid (EDTA)FDA Link 01/2020
1	Dabigatran FDA Link 01/2019
1	idarucizumabIBA 01/2019
1	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 08/2018
1	Oxygen (Dioxygen)IBA 08/2018

Therapy/Procedure

69	Therapeutics 02/2022 - 01/2002
32	Thrombectomy 02/2022 - 03/2015
13	Thrombolytic Therapy 06/2016 - 11/2002
9	Secondary Prevention 10/2019 - 02/2003
6	Stents 01/2019 - 03/2015
5	Carotid Endarterectomy 10/2019 - 08/2002
5	Treatment Delay 05/2017 - 04/2014
4	Contraindications 01/2020 - 10/2017
4	Time-to-Treatment 05/2019 - 05/2010
3	Aftercare (After-Treatment) 01/2019 - 07/2013
3	Institutionalization (Institutionalized Persons) 10/2004 - 12/2002
2	Length of Stay 01/2021 - 04/2003
2	Patient Readmission 12/2020 - 07/2015
2	Early Ambulation 11/2020 - 01/2011
2	Catheters 01/2020 - 01/2018
1	Critical Care (Surgical Intensive Care) 09/2021
1	Subacute Care 12/2020
1	Punctures 01/2019
1	Embolectomy 10/2018